Fusion Antibodies Plc (GB:FAB) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fusion Antibodies Plc has secured a contract to develop a therapeutic antibody to combat a chronic disease, expecting to generate £200,000 in revenue within the current financial year, along with future royalties from commercial sales. The company continues to leverage its expertise in antibody engineering, working closely with a long-standing US biotech client, with whom they have an ongoing $650,000 project. Fusion Antibodies’ growth strategy focuses on accelerating the drug development process for pharmaceutical and diagnostic companies.
For further insights into GB:FAB stock, check out TipRanks’ Stock Analysis page.